June 2019 Digital Edition


Pipeline watch: we look closely at drugs in phase 2, phase 3 or recently approved for basal cell carcinoma and melanoma. Plus, treating patients with autism, and the physician's impact on regulations and pay.


Download the digital edition


Subscribe to Dermatology Times!   Print & Digital / eNewsletter


Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.